A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Purpose
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effective at treating the cancer, there are still concerns about the side effects of such treatment. Side effects or unintended health conditions that arise due to treatment include learning difficulties, hearing loss or other issues in performing daily activities. Standard therapy for newly diagnosed average-risk or low-risk medulloblastoma includes surgery, radiation therapy, and chemotherapy (including cisplatin). Cisplatin may cause hearing loss as a side effect. In the average-risk medulloblastoma patients, this trial tests whether the addition of sodium thiosulfate (STS) to standard of care chemotherapy and radiation therapy reduces hearing loss. Previous studies with STS have shown that it may help reduce or prevent hearing loss caused by cisplatin. In the low-risk medulloblastoma patients, the study tests whether a less intense therapy (reduced radiation) can provide the same benefits as the more intense therapy. The less intense therapy may cause fewer side effects. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. The overall goals of this study are to see if giving STS along with standard treatment (radiation therapy and chemotherapy) will reduce hearing loss in medulloblastoma patients and to compare the overall outcome of patients with medulloblastoma treated with STS to patients treated without STS on a previous study in order to make sure that survival and recurrence of tumor is not worsened.
Condition
- Childhood Medulloblastoma
Eligibility
- Eligible Ages
- Between 4 Years and 21 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- PRE-ENROLLMENT: Patients must be ≥ 4 years and ≤ 21 years of age at the time of enrollment - PRE-ENROLLMENT: Patient is suspected to have newly-diagnosed medulloblastoma by institutional diagnosis - Please note: Patients with a pending result of CSF cytology tests are eligible for NCI-2014-02057 (APEC14B1-Central Nervous System [CNS]) and CNS/Medulloblastoma Pre Enrollment Eligibility Screening - PRE-ENROLLMENT: The patient and/or their parents or legal guardians must have signed informed consent for APEC14B1 Part A - Eligibility Screening and consent for the Molecular Characterization Initiative (MCI) - PRE-ENROLLMENT: The required specimens are projected to be submitted under APEC14B1-CNS as soon as possible, preferably within 5 days of definitive surgery - PRE-ENROLLMENT: All patients must have rapid central pathology review under APEC14B1-CNS prior to study enrollment on ACNS2031 step 1 in order to avoid discordant diagnoses and to verify diagnosis criterion for treatment on ACNS2031. - Note: Patients with a pending result of CSF cytology tests are eligible for the rapid central pathology screening review. Confirmation of CSF negativity is needed for enrollment on the ACNS2031 protocol - PRE-ENROLLMENT: All patients must have rapid central molecular screening review under APEC14B1-CNS prior to study enrollment on ACNS2031 step 1, in order to avoid discordant diagnoses and to verify diagnosis criterion for treatment on ACNS2031 - PRE-ENROLLMENT: All patients who have histopathology confirmed must have rapid central imaging screening review under APEC14B1 prior to study enrollment on ACNS2031 step 1 - Note: Patients must not have metastatic disease on cranial or spinal MRI. Patients with > 1.5 cm^2 residual tumor after initial surgical resection may undergo a second surgical resection prior to subsequent therapy to render them eligible for this study. The day of the second resection to remove residual tumor will be regarded as the day of definitive surgery (Day 0) and must be within a month (31 days) of the initial resection - PRE-ENROLLMENT: All patients who have histopathology confirmed must have rapid central audiology review under APEC14B1-CNS prior to study enrollment on ACNS2031 step 1 - Patients must be >= 4 years and =< 21 years of age at the time of enrollment - Patients must be newly diagnosed and have eligibility confirmed by rapid central pathology and molecular screening reviews performed on APEC14B1 and via the Molecular Characterization Initiative - Average-risk cohort - Clinico-pathologic criteria: - M0 disease - No diffuse anaplastic histology AND - Molecular criteria: - SHH, p53wt, GLI2 normal, MYCN normal, no chromosome 14q loss - Group 3, MYC normal, no isochromosome 17q - Group 4, no chromosome 11 loss - Low-risk features cohort - Clinico-pathologic criteria: - M0 disease - No diffuse anaplastic histology AND - Molecular criteria: - Group 4, chromosome 11 loss - Patients must have negative lumbar CSF cytology - Note: CSF cytology for staging should be performed no sooner than 14 days post operatively to avoid false positive CSF. Ideally, CSF should be obtained between day 14 and day 21 to allow for final staging status before enrollment onto the study. Patients with positive CSF cytology obtained 0 to 14 days after surgery should have cytology repeated to determine eligibility and final CSF status. Patients with negative CSF cytology from lumbar puncture obtained 0 to 14 days after surgery do not need cytology repeated. Patients with negative CSF cytology from lumbar puncture obtained prior to surgery do not need cytology repeated post-operatively - Patients must have eligibility confirmed by Rapid Central Imaging Review performed on APEC14B1. Patients must have =< 1.5 cm^2 cross-sectional area of residual tumor. Whole brain MRI with and without gadolinium and spine MRI with gadolinium must be performed - Patients must weigh > 10 kg - Patients must be enrolled, and protocol therapy must be projected to begin, no later than 31 days after definitive diagnostic surgery (day 0) - Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to enrollment) - Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to enrollment) - Hemoglobin >= 8.0 g/dL (may receive red blood cell count [RBC] transfusions) (within 7 days prior to enrollment) - A serum creatinine (within 7 days prior to enrollment) based on age/sex as follows: - 4 to < 6 years (age); 0.8 mg/dL (male) 0.8 mg/dL (female) - 6 to < 10 years (age); 1 mg/dL (male) 1 mg/dL (female) - 10 to < 13 years (age); 1.2 mg/dL (male) 1.2 mg/dL (female) - 13 to < 16 years (age); 1.5 mg/dL (male) 1.4 mg/dL (female) - >= 16 years (age); 1.7 mg/dL (male) 1.4 mg/dL (female) OR a 24 hour urine Creatinine clearance >= 70 mL/min/1.73 m^2 (within 7 days prior to enrollment) OR a glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 (within 7 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard) - Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment) - Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (within 7 days prior to enrollment) - Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L - Central nervous system function defined as: - Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled - Patients must not be in status epilepticus, a coma or assisted ventilation at the time of study enrollment - Auditory function defined as: - Patients must have normal hearing (defined as International Society of Pediatric Oncology [SIOP] grade 0) in at least one ear confirmed by rapid central audiology review performed on APEC14B1 prior to enrollment - All patients and/or their parents or legal guardians must sign a written informed consent - All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria
- Patients with metastatic disease by either MRI evaluation or lumbar CSF cytology are not eligible. Patients who are unable to undergo a lumbar puncture for assessment of CSF cytology are ineligible - Patients must not have received any prior radiation therapy or chemotherapy (tumor-directed therapy) other than surgical intervention and/or corticosteroids - Patients must not have any known hypersensitivity to STS, sulfates/sulfites, or other thiol agents (e.g., amifostine, n-acetylcysteine, MESNA, and captopril) - Pregnancy and Breastfeeding: - Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential - Lactating females who plan to breastfeed their infants - Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Treatment (chemoradiotherapy, maintenance) |
See Detailed Description. |
|
Recruiting Locations
Mobile 4076598, Alabama 4829764 36604
Site Public Contact
800-388-8721
Phoenix 5308655, Arizona 5551752 85016
Site Public Contact
602-546-0920
Little Rock 4119403, Arkansas 4099753 72202-3591
Site Public Contact
501-364-7373
Loma Linda 5367696, California 5332921 92354
Site Public Contact
909-558-4050
Long Beach 5367929, California 5332921 90806
Site Public Contact
562-933-5600
Los Angeles 5368361, California 5332921 90027
Site Public Contact
323-361-4110
Madera 5369568, California 5332921 93636
Oakland 5378538, California 5332921 94611
Orange 5379513, California 5332921 92868
San Diego 5391811, California 5332921 92123
Site Public Contact
858-966-5934
San Francisco 5391959, California 5332921 94158
Aurora 5412347, Colorado 5417618 80045
Hartford 4835797, Connecticut 4831725 06106
Site Public Contact
860-545-9981
New Haven 4839366, Connecticut 4831725 06520
Wilmington 4145381, Delaware 4142224 19803
Washington D.C. 4140963, District of Columbia 4138106 20010
Fort Myers 4155995, Florida 4155751 33908
Hollywood 4158928, Florida 4155751 33021
Jacksonville 4160021, Florida 4155751 32207
Miami 4164138, Florida 4155751 33136
Site Public Contact
305-243-2647
Miami 4164138, Florida 4155751 33155
Site Public Contact
888-624-2778
Orlando 4167147, Florida 4155751 32806
Orlando 4167147, Florida 4155751 32827
Pensacola 4168228, Florida 4155751 32504
Tampa 4174757, Florida 4155751 33607
Atlanta 4180439, Georgia 4197000 30329
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-355-3046
Peoria 4905687, Illinois 4896861 61637
Site Public Contact
888-226-4343
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Indianapolis 4259418, Indiana 4921868 46202
Site Public Contact
800-248-1199
Iowa City 4862034, Iowa 4862182 52242
Site Public Contact
800-237-1225
Louisville 4299276, Kentucky 6254925 40202
New Orleans 4335045, Louisiana 4331987 70118
Site Public Contact
504-894-5377
Baltimore 4347778, Maryland 4361885 21215
Site Public Contact
410-601-9083
Baltimore 4347778, Maryland 4361885 21287
Boston 4930956, Massachusetts 6254926 02114
Site Public Contact
877-726-5130
Ann Arbor 4984247, Michigan 5001836 48109
Site Public Contact
800-865-1125
Detroit 4990729, Michigan 5001836 48201
Royal Oak 5007804, Michigan 5001836 48073
Site Public Contact
248-551-7695
Minneapolis 5037649, Minnesota 5037779 55404
Rochester 5043473, Minnesota 5037779 55905
Site Public Contact
855-776-0015
Jackson 4431410, Mississippi 4436296 39216
Site Public Contact
601-815-6700
Kansas City 4393217, Missouri 4398678 64108
St Louis 4407066, Missouri 4398678 63104
Site Public Contact
314-268-4000
St Louis 4407066, Missouri 4398678 63110
Omaha 5074472, Nebraska 5073708 68114
Site Public Contact
402-955-3949
Omaha 5074472, Nebraska 5073708 68198
New Brunswick 5101717, New Jersey 5101760 08901
Newark 5101798, New Jersey 5101760 07112
Paterson 5102466, New Jersey 5101760 07503
Albany 5106834, New York 5128638 12208
Site Public Contact
518-262-5513
Buffalo 5110629, New York 5128638 14263
New Hyde Park 5128514, New York 5128638 11040
Site Public Contact
718-470-3460
New York 5128581, New York 5128638 10029
Stony Brook 5139865, New York 5128638 11794
Site Public Contact
800-862-2215
Syracuse 5140405, New York 5128638 13210
Site Public Contact
315-464-5476
The Bronx 5110266, New York 5128638 10467
Valhalla 5142090, New York 5128638 10595
Site Public Contact
914-594-3794
Chapel Hill 4460162, North Carolina 4482348 27599
Charlotte 4460243, North Carolina 4482348 28203
Site Public Contact
800-804-9376
Greenville 4469160, North Carolina 4482348 27834
Winston-Salem 4499612, North Carolina 4482348 27157
Site Public Contact
336-713-6771
Fargo 5059163, North Dakota 5690763 58122
Akron 5145476, Ohio 5165418 44308
Site Public Contact
330-543-3193
Cincinnati 4508722, Ohio 5165418 45229
Cleveland 5150529, Ohio 5165418 44106
Site Public Contact
216-844-5437
Columbus 4509177, Ohio 5165418 43205
Dayton 4509884, Ohio 5165418 45404
Site Public Contact
800-228-4055
Toledo 5174035, Ohio 5165418 43606
Oklahoma City 4544349, Oklahoma 4544379 73104
Portland 5746545, Oregon 5744337 97227
Site Public Contact
503-413-2560
Portland 5746545, Oregon 5744337 97239
Danville 5186327, Pennsylvania 6254927 17822
Philadelphia 4560349, Pennsylvania 6254927 19104
Pittsburgh 5206379, Pennsylvania 6254927 15224
Providence 5224151, Rhode Island 5224323 02903
Site Public Contact
401-444-1488
Columbia 4575352, South Carolina 4597040 29203
Greenville 4580543, South Carolina 4597040 29605
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Nashville 4644585, Tennessee 4662168 37232
Site Public Contact
800-811-8480
Austin 4671654, Texas 4736286 78723
Dallas 4684888, Texas 4736286 75230
Site Public Contact
972-566-5588
Dallas 4684888, Texas 4736286 75390
El Paso 5520993, Texas 4736286 79905
San Antonio 4726206, Texas 4736286 78207
San Antonio 4726206, Texas 4736286 78229
Charlottesville 4752031, Virginia 6254928 22908
Richmond 4781708, Virginia 6254928 23298
Seattle 5809844, Washington 5815135 98105
Site Public Contact
866-987-2000
Spokane 5811696, Washington 5815135 99204
Tacoma 5812944, Washington 5815135 98405
Madison 5261457, Wisconsin 5279468 53792
Marshfield 5261969, Wisconsin 5279468 54449
Milwaukee 5263045, Wisconsin 5279468 53226
More Details
- NCT ID
- NCT05382338
- Status
- Recruiting
- Sponsor
- Children's Oncology Group
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate the efficacy of sodium thiosulfate (STS) infusion administered during cisplatin-containing chemotherapy cycles (compared to a historical cohort selected from ACNS0331 which received chemotherapy without STS) in reducing hearing loss in children with newly-diagnosed average-risk medulloblastoma. II. To estimate and monitor event-free survival (EFS) in this study against a carefully selected cohort from ACNS0331 to guard against loss of efficacy due to STS. SECONDARY OBJECTIVES: I. To estimate and monitor overall survival (OS) in this study against a carefully selected control cohort from ACNS0331. II. To estimate the incidence of ototoxicity-related cisplatin dose modifications in the average-risk cohort. III. To estimate the incidence of cisplatin-related nephrotoxicity in both the average-risk and low-risk cohorts. IV. To evaluate full scale intelligence neurocognitive outcomes and trajectories of patients with average-risk medulloblastoma treated with STS compared to the control cohort from ACNS0331. V. To evaluate quality of life and psychosocial outcomes and trajectories of patients with average-risk medulloblastoma treated with STS compared to published norms. VI. To estimate and monitor EFS, OS, and patterns of recurrence in patients with low-risk features treated using a reduced craniospinal radiation approach. VII. To evaluate the trajectory of hearing loss in medulloblastoma patients treated with STS. VIII. To evaluate household material hardship as a social determinant of neurocognitive, quality of life, and psychosocial outcomes in patients with average-risk and low risk medulloblastoma. EXPLORATORY OBJECTIVES: I. To obtain paired blood and tumor tissue to be banked for future biology studies involving comprehensive molecular analysis, including but not limited to whole exome sequencing, ribonucleic acid (RNA) sequencing, and methylation. II. To bank blood and cerebrospinal fluid for future studies. III. To evaluate attention, processing speed, memory, and executive function neurocognitive outcomes and trajectories, as well as hearing-related quality of life outcomes and trajectories, of patients with average-risk medulloblastoma treated with STS. IV. To evaluate neurocognitive, quality of life, and psychosocial outcomes of patients with low-risk features treated using a reduced craniospinal radiation approach. OUTLINE: CHEMORADIOTHERAPY: Patients undergo radiation therapy 5 days per week for 6 weeks (weeks 1-6) and receive vincristine intravenously (IV) once weekly on weeks 2-7 in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Beginning 4 weeks after chemoradiotherapy, patients receive lomustine orally (PO) on day 1 of cycles 1, 2, 4, 5, 7, and 8, cisplatin IV over 6 hours on day 1 of cycles 1, 2, 4, 5, 7, and 8, sodium thiosulfate IV over 15 minutes on day 1 of cycles 1, 2, 4, 5, 7, and 8, and cyclophosphamide IV over 30-60 minutes on days 1 and 2 of cycles 3, 6, and 9. Patients also receive vincristine IV on days 1, 8, and 15 of cycles 1, 2, 4, 5, 7, and 8, and on days 1 and 8 of cycles 3, 6, and 9. Treatment repeats every 6 weeks (cycles 1, 2, 4, 5, 7 and 8) or every 4 weeks (cycles 3, 6, and 9) for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo magnetic resonance imaging (MRI) and collection of cerebrospinal fluid (CSF) throughout the study. Patients may also optionally undergo blood sample collection throughout the study. After completion of study treatment, patients are followed up every 3 months for years 1-2, every 6 months for years 3-4, and then annually for years 5-10.